5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details
臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03058965 (ClinicalTrials.gov) | November 29, 2016 | 12/1/2017 | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers | Alzheimer Disease;Healthy Volunteers;Progressive Supranuclear Palsy | Drug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscan | Molecular NeuroImaging | NULL | Completed | 50 Years | 90 Years | All | 12 | Early Phase 1 | United States |